Luminos® is Discovery Life Sciences’ clinical genomic profiling platform: IVDR-compliant, in-house, and purpose-built for oncology clinical trials. Luminos® Comprehensive is available now. Luminos® Liquid launches Fall 2026.
Oncology clinical trials demand genomic answers at enrollment speed. Too many sponsors compromise, accepting slower turnaround from outsourced reference labs or narrower panels that miss the biomarker they needed to find. Regulatory delays due to burdensome performance studies frequently delay EU clinical trial starts relative to the rest of the world. Luminos is built around a different premise: that the combination of panel breadth, in-house operational control, and IVDR regulatory standing should not require a trade-off.
Luminos® Comprehensive delivers 164-gene pan-tumor profiling in 7 to 10 days from our Kassel, Germany facility, deployed as a CAP/CLIA compliant, in-house device under Health Institution status, one of the few configurations in the EU market that enables prospective clinical trial use without a performance study. It is the clinical genomics offering Discovery Life Sciences has built to support sponsors at the most consequential moment of a trial: enrollment.
Available Now
164-gene pan-tumor tissue CGP panel. IVDR-compliant, in-house deployment at Kassel, Germany. 7-to-10-day turnaround. Dedicated project and data support. The comprehensive oncogene profile for enrollment screening, novel target identification, and companion diagnostic development.
Key specs:
Launching Fall 2026
Liquid biopsy genomic profiling with DNA and RNA inputs. IVDR-compliant, in-house deployment at Kassel. Purpose-built for studies requiring serial monitoring, treatment response assessment, or tissue-inaccessible cases.
Key specs:
Luminos® is the genomic profiling platform through which Discovery Life Sciences enters the clinical genomics market, purpose-built for oncology clinical trials and anchored in validated science, regulatory compliance, and operational speed.
Discovery Life Sciences supports the full drug development cycle across biospecimen procurement, specialty lab services, and genomic and proteomic analysis. Luminos® is Discovery Life Sciences’ clinical genomics offering within a Specialty Lab Services portfolio that also delivers research-grade genomics, proteomics (Olink protein profiling and mass spectrometry), molecular pathology (IHC, mIF, ISH), clinical flow cytometry, and companion diagnostic services from development through post-approval. For sponsors seeking an integrated single-partner approach from sample collection to multi-omic data delivery, Luminos® is the clinical genomics anchor within that broader capability.
